OBJECTIVES: The purpose of this study was to investigate circulating pro-B-type natriuretic peptide (proBNP(1-108)) in the general community and evaluate its ability to detect left ventricular (LV) dysfunction. BACKGROUND: The current concept for cardiac endocrine function is that, in response to cardiac stress, the heart secretes B-type natriuretic peptide (BNP(1-32)) and amino-terminal pro-B-type natriuretic peptide (NT-proBNP(1-76)) after intracardiac cleavage of their molecular precursor, proBNP(1-108). We hypothesized that proBNP(1-108) circulates in normal human subjects and that it is a useful biomarker for LV dysfunction. METHODS: Our population-based study included a cohort of 1,939 adults (age ≥45 years) from Olmsted County, Minnesota, with 672 participants defined as healthy. Subjects underwent in-depth clinical characterization, detailed echocardiography, and measurement of proBNP(1-108). Independent factors associated with proBNP(1-108) and test characteristics for the detection of LV dysfunction were determined. RESULTS: ProBNP(1-108) in normal humans was strongly influenced by sex, age, heart rate, and body mass index. The median concentration was 20 ng/l with a mean proBNP(1-108) to NT-proBNP(1-76) ratio of 0.366, which decreased with heart failure stage. ProBNP(1-108) was a sensitive (78.8%) and specific (86.1%) biomarker for detecting LV systolic dysfunction, which was comparable to BNP(1-32), but less than NT-proBNP(1-76), in several subsets of the population. CONCLUSIONS: ProBNP(1-108) circulates in the majority of healthy humans in the general population and is a sensitive and specific biomarker for the detection of systolic dysfunction. The proBNP(1-108) to NT-proBNP(1-76) ratio may provide insights into altered proBNP(1-108) processing during heart failure progression. Thus, this highly specific assay for proBNP(1-108) provides important new insights into the biology of the BNP system.
OBJECTIVES: The purpose of this study was to investigate circulating pro-B-type natriuretic peptide (proBNP(1-108)) in the general community and evaluate its ability to detect left ventricular (LV) dysfunction. BACKGROUND: The current concept for cardiac endocrine function is that, in response to cardiac stress, the heart secretes B-type natriuretic peptide (BNP(1-32)) and amino-terminal pro-B-type natriuretic peptide (NT-proBNP(1-76)) after intracardiac cleavage of their molecular precursor, proBNP(1-108). We hypothesized that proBNP(1-108) circulates in normal human subjects and that it is a useful biomarker for LV dysfunction. METHODS: Our population-based study included a cohort of 1,939 adults (age ≥45 years) from Olmsted County, Minnesota, with 672 participants defined as healthy. Subjects underwent in-depth clinical characterization, detailed echocardiography, and measurement of proBNP(1-108). Independent factors associated with proBNP(1-108) and test characteristics for the detection of LV dysfunction were determined. RESULTS: ProBNP(1-108) in normal humans was strongly influenced by sex, age, heart rate, and body mass index. The median concentration was 20 ng/l with a mean proBNP(1-108) to NT-proBNP(1-76) ratio of 0.366, which decreased with heart failure stage. ProBNP(1-108) was a sensitive (78.8%) and specific (86.1%) biomarker for detecting LV systolic dysfunction, which was comparable to BNP(1-32), but less than NT-proBNP(1-76), in several subsets of the population. CONCLUSIONS: ProBNP(1-108) circulates in the majority of healthy humans in the general population and is a sensitive and specific biomarker for the detection of systolic dysfunction. The proBNP(1-108) to NT-proBNP(1-76) ratio may provide insights into altered proBNP(1-108) processing during heart failure progression. Thus, this highly specific assay for proBNP(1-108) provides important new insights into the biology of the BNP system.
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Eric P Leip; Emelia J Benjamin; Peter W F Wilson; Patrice Sutherland; Torbjorn Omland; Ramachandran S Vasan Journal: Am J Cardiol Date: 2002-08-01 Impact factor: 2.778
Authors: Paul M McKie; Alessandro Cataliotti; Brian D Lahr; Fernando L Martin; Margaret M Redfield; Kent R Bailey; Richard J Rodeheffer; John C Burnett Journal: J Am Coll Cardiol Date: 2010-05-11 Impact factor: 24.094
Authors: A Cataliotti; L S Malatino; M Jougasaki; C Zoccali; P Castellino; G Giacone; I Bellanuova; R Tripepi; G Seminara; S Parlongo; B Stancanelli; G Bonanno; P Fatuzzo; F Rapisarda; P Belluardo; S S Signorelli; D M Heublein; J G Lainchbury; H K Leskinen; K R Bailey; M M Redfield; J C Burnett Journal: Mayo Clin Proc Date: 2001-11 Impact factor: 7.616
Authors: Alan S Maisel; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Paul Clopton; Philippe G Steg; Arne Westheim; Catherine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough Journal: N Engl J Med Date: 2002-07-18 Impact factor: 91.245
Authors: Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett Journal: J Am Coll Cardiol Date: 2002-09-04 Impact factor: 24.094
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan Journal: Circulation Date: 2004-02-10 Impact factor: 29.690
Authors: Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Caryn S Barnet; Xiaoxia Liu; Simon C Body; Charles D Collard; Stanton K Shernan; Jochen D Muehlschlegel; Petr Jarolim; Amanda A Fox Journal: J Cardiothorac Vasc Anesth Date: 2014-11-11 Impact factor: 2.628
Authors: Brenda K Huntley; Sharon M Sandberg; Denise M Heublein; S Jeson Sangaralingham; John C Burnett; Tomoko Ichiki Journal: Circ Heart Fail Date: 2014-10-22 Impact factor: 8.790
Authors: Sara J Holditch; Claire A Schreiber; Ryan Nini; Jason M Tonne; Kah-Whye Peng; Aron Geurts; Howard J Jacob; John C Burnett; Alessandro Cataliotti; Yasuhiro Ikeda Journal: Hypertension Date: 2015-05-11 Impact factor: 10.190
Authors: Jason M Tonne; Jarryd M Campbell; Alessandro Cataliotti; Seiga Ohmine; Tayaramma Thatava; Toshie Sakuma; Fima Macheret; Brenda K Huntley; John C Burnett; Yasuhiro Ikeda Journal: Clin Chem Date: 2011-04-11 Impact factor: 8.327
Authors: Fima Macheret; Denise Heublein; Lisa C Costello-Boerrigter; Guido Boerrigter; Paul McKie; Diego Bellavia; Sarah Mangiafico; Yasuhiro Ikeda; Kent Bailey; Christopher G Scott; Sharon Sandberg; Horng H Chen; Lorenzo Malatino; Margaret M Redfield; Richard Rodeheffer; John Burnett; Alessandro Cataliotti Journal: J Am Coll Cardiol Date: 2012-10-16 Impact factor: 24.094